In the SURMOUNT-1 trial, tirzepatide produced average weight loss of 15-22.5% of body weight over 72 weeks depending on dose
In SURMOUNT-1 , a 72-week Phase 3 double-blind trial in 2,539 adults with obesity (or overweight with a complication) but without diabetes, once-weekly tirzepatide produced mean weight changes of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo, with 5057% of participants on the higher doses losing at least 20% of body weight
Very effective for retinal inflammation (uveitis, macular edema) but significant side effects (cataract formation, pressure elevation, infection risk)
It comes in the in a convenient 10 x 10 packaging
The effects of glutathione injections on hyperpigmentation, sunspots, wrinkles, acne, as well as melasma are reduced by eliminating toxins and free radicals from the body
& Seino, Y